Kymera Therapeutics, Inc. KYMR shares rallied 7.8% in the last trading session to close at $40.12. This move can be attributable to notable volume with a higher number of shares being traded than ...

KBC Group NV boosted its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 53.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 2,151 shares of the company’s ...

Begin your TipRanks Premium journey today. Kymera Therapeutics (KYMR) Company Description: Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating ...

Kymera Therapeutics, Inc. announced its participation in two upcoming investor events: the Guggenheim SMID Cap Biotechnology Conference on February 6 and the Oppenheimer 35th Annual Healthcare ...

Kymera Therapeutics announced its clinical development plans for 2025, focusing on its oral degrader programs targeting immunological diseases. The company is currently conducting a Phase 1 trial ...

Shares of Kymera Therapeutics (NASDAQ:KYMR) spiked on Tuesday after the developer of oral protein degraders outlined its 2025 outlook at the ongoing J.P. Morgan Healthcare Conference. According to ...

Jan. 14, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with ...

WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader ...